| Features: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Caffeic Acid Phenethyl Ester (CAPE) — CAPE is a propolis-derived phenolic ester and bioactive honeybee-hive constituent with pleiotropic anti-inflammatory and antineoplastic signaling effects. It is best classified as a natural polyphenolic small molecule and experimental adjunct candidate rather than an approved anticancer drug. Standard abbreviations include CAPE; common chemical naming includes caffeic acid phenethyl ester and phenethyl caffeate. CAPE is most strongly associated with poplar-type propolis chemistry, but it is also available as an ingredient in some dietary-supplement products. Current oncology relevance remains preclinical to early translational, with growing interest in chemosensitization and radiosensitization but no established cancer indication. Primary mechanisms (ranked):
Bioavailability / PK relevance: Oral translation is constrained by poor aqueous solubility, limited absorption, esterase-sensitive disposition, and substantial hydrolysis to caffeic acid in vivo. Rat PK work supports measurable exposure after oral dosing, but CAPE analogues with improved permeability outperform parent CAPE. Formulation strategies are therefore mechanistically relevant for systemic use. In-vitro vs systemic exposure relevance: Many direct anticancer studies use roughly 10–60 μM exposure, with some effects emerging near or above this range; those concentrations may exceed or stress the upper edge of practical systemic exposure with simple oral delivery. Tumor-directed claims should therefore be weighted more heavily when supported by in vivo xenograft, radiosensitization, or formulation-enabled data rather than cell culture alone. Clinical evidence status: Predominantly preclinical with in vitro, xenograft, and ex vivo support; small translational signals exist for radiosensitization/radioprotection concepts, but there is no established oncology trial program or approved cancer use for CAPE itself. CAPE — Cancer vs Normal Cell Pathway Map
TSF legend: P: 0–30 min; R: 30 min–3 hr; G: >3 hr |
| Source: |
| Type: |
| 5‑Lipoxygenase (5‑LO) is an enzyme that catalyzes the oxygenation of arachidonic acid to produce leukotrienes and other bioactive lipid mediators. It is a member of the lipoxygenase family and plays a key role in inflammatory responses. 5‑LO is overexpressed in various malignancies, particularly those with a strong inflammatory component. Overexpression of 5‑LO is often detected in tumor cells as well as in stromal cells (e.g., tumor-associated macrophages) within the tumor microenvironment. Elevated 5‑LO expression is frequently linked with increased tumor proliferation, enhanced angiogenesis, and higher metastatic potential—factors that often correlate with a poor prognosis. |
| 5772- | CAPE, | The Pluripotent Activities of Caffeic Acid Phenethyl Ester |
| - | Review, | Var, | NA |
| 5757- | CAPE, | Caffeic acid phenethyl ester (CAPE): pharmacodynamics and potential for therapeutic application |
| - | Review, | Nor, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:395 Target#:1090 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid